How Adaptive Trial Designs Can Increase Efficiency in Psychiatric Drug Development: A Case Study.

This paper uses a recently completed study to illustrate how adaptive trial designs can increase efficiency of psychiatric drug development. The design employed allowed a continuous reassessment of the estimated dose-response such that patients were randomized in a double-blind fashion to one of sev...

Descripción completa

Detalles Bibliográficos
Publicado en:Innovations in Clinical Neuroscience Vol. 8; no. 7; pp. 26 - 35
Autores principales: SHEN, JOAN, PRESKORN, SHELDON, DRAGALIN, VLADIMIR, SLOMKOWSKI, MARY, PADMANABHAN, S. KRISHNA, FARDIPOUR, PARVIN, SHARMA, AMARNATH, KRAMS, MICHAEL
Formato: case study clinical trial research tables/charts Journal Article
Publicado: Matrix Medical Communications, LLC Jul2011
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=65412041&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 65412041
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        21588333
        DAD5
      jtl: Innovations in Clinical Neuroscience
      issn: 21588333
      maglogo: N
    pubinfo:
      dt: Jul2011
      vid: 8
      iid: 7
      pid: 33670
      pub: Matrix Medical Communications, LLC
      place: West Chester, Pennsylvania
    artinfo:
      ui:
        65412041
        65412041
        104689709
        65412041
      ppf: 26
      ppct: 9
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: How Adaptive Trial Designs Can Increase Efficiency in Psychiatric Drug Development: A Case Study.
      aug:
        au:
          SHEN, JOAN
          PRESKORN, SHELDON
          DRAGALIN, VLADIMIR
          SLOMKOWSKI, MARY
          PADMANABHAN, S. KRISHNA
          FARDIPOUR, PARVIN
          SHARMA, AMARNATH
          KRAMS, MICHAEL
        affil: Senior Director, Pfizer Inc., Collegeville, Pennsylvania
      sug:
        subj:
          Drug Design
          Antipsychotic Agents Therapeutic Use
          Clinical Trials
          Antipsychotic Agents Administration and Dosage
          Schizophrenia Drug Therapy
          Drugs, Investigational
          Risperidone Administration and Dosage
          Descriptive Statistics
          Human
          Simulations
          United States
          Adult
          Middle Age
          Male
          Female
          Treatment Outcomes
          Dose-Response Relationship, Drug
          Psychological Tests
          Scales
          Adult: 19-44 years
          Middle Aged: 45-64 years
          Male
          Female
      ab: This paper uses a recently completed study to illustrate how adaptive trial designs can increase efficiency of psychiatric drug development. The design employed allowed a continuous reassessment of the estimated dose-response such that patients were randomized in a double-blind fashion to one of seven doses of the investigational drug, placebo, or active comparator. The study design also permitted early detection of futility allowing for early study termination. By using the adaptive trial design approach, only 202 patients were needed to make the determination of futility. In contrast, a conventional design would have required enrollment of 450 patients and considerably more time and expense to reach the same conclusion. Adaptive trial designs are important at this time when many pharmaceutical companies are abandoning the development of psychiatric medications because of the inefficiency of conventional approaches.
      pubtype: Academic Journal
      doctype:
        case study
        clinical trial
        research
        tables/charts
        Journal Article
      ougenre: Unknown
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N